Long-term renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion/deletion genotype?

Diabetes Care

Volumn 26, Issue 5, 2003, Pages 1501-1506

  Andersen, Steen ^a   Tarnow, Lise ^a   Cambien, Francois ^b   Rossing, Peter ^a   Juhl, Tina R ^a   Deinum, Jaap ^c   Parving, Hans Henrik ^a,d  

^a STENO DIABETES CENTER   (Denmark)

^b INSERM   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LOSARTAN;

ADULT; ALLELE; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; GENE DELETION; GENE INSERTION; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHOLESTEROL, HDL; CREATININE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DNA TRANSPOSABLE ELEMENTS; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POTASSIUM; RISK FACTORS; SEQUENCE DELETION;

EID: 0037816365     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.5.1501     Document Type: Article

References (40)

1. Tarnow L, Gluud C, Parving H-H: Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 13:1125-1130, 1998
2. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, Kawaguchi Y, Kubo H, Ichikawa I, Sakai O: Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 96:2162-2169, 1995
3. Parving H-H, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F: Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 313:591-594, 1996
4. Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, Luong L-A, Fuller JH, the Euclid Study Group: Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID randomized controlled trial. Diabetes 47:1507-1511, 1998
5. Vleming LJ, van der Pijl JW, Lemkes HHPJ, Westendorp RGJ, Maassen JA, Daha MR, van Es LA, van Kooten C: The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. Clin Nephrol 51:133-140, 1999
6. Björck S, Blohmé G, Sylvén C, Mulec H: Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy. Nephrol Dial Transplant 12:67-70, 1997
7. Schmidt S, Ritz E: Angiotensin I converting enzyme gene polymorphism and diabetic nephropathy in type II diabetes. Nephrol Dial Transplant 12:37-41, 1997
8. Schmidt S, Strojek K, Grzeszczak W, Bergis K, Ritz E: Excess of DD homozygotes in haemodialysed patients with type II diabetes. Nephrol Dial Transplant 12:427-429, 1997
9. Harden PN, Geddes C, Rowe PA, McIlroy JH, Boulton-Jones M, Rogers S, Junor BJR, Briggs JD, Connell JMC, Jardine AG: Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 345:1540-1542, 1995
10. Yoshida H, Kuriyama S, Atsumi Y, Tomonari H, Mitarai T, Hamaguchi A, Kubo H, Kawaguchi Y, Kon V, Matsuoka K, Ichikawa I, Sakai O: Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 50:657-664, 1996
11. van Essen GG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer H, Apperloo AJ, de Jong PE: Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotecrive therapy. Lancet 347:94-95, 1996
12. Perna A, Ruggenenti P, Testa A, Spoto B, Benini R, Misefari V, Remuzzi G, Zoccali C: ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int 57:274-281, 2000
13. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Parving H-H: Lack of relationship between an insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 44:489-494, 1995
14. Marre M, Bernadet P, Gallois Y, Savagner F, Guyenne T-T, Hallab M, Cambien F, Passa PH, Alhenc-Gelas F: Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43:384-388, 1994
15. Jacobsen P, Rossing K, Rossing P, Tamow L, Mallet C, Poirier O, Cambien F, Parving, H-H: Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 53:1002-1006, 1998
16. Haas M, Yitmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll HK, Wallner M, Auinger M, Arias I, Schneider B, Mayer G: Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease: Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. Kidney Blood Press Res 21:66-69, 1998
17. van der Kleij FG, Navis GJ, Gansevoort RT, Heeg JE, Scheffer H, de Zeeuw D, de Jong PE: ACE polymorphism does not determine short-term renal response to ACE inhibition in proteinuric patients. Nephrol Dial Transplant 12 (Suppl. 2):42-46, 1997
18. Parving H-H, Andersen AR, Smidt UM, Svendsen PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet i: 1175-1179, 1983
19. Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH: Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Kidney Int 62:192-198, 2002
20. Rigat B, Hubert C, Corvol P, Soubrier F: PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP 1) (dipeptidyl-carboxy peptidose 1). Nucleic Acids Res 20:1433-1433, 1992
21. Fogarty DG, Maxwell AP, Doherty CC, Hughes AE, Nevin NC: Ace gene typing. Lancet 343:851, 1994
22. Bröchner-Mortensen J, Rödbro P: Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 36:35-45, 1976
23. Bröchner-Mortensen J: A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 30:271-274, 1972
24. Maroni BJ, Steinman TI, Mitch WE: A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 27:58-65, 1985
25. Kappelgaard AM, Nielsen MD, Giese J: Measurement of angiotensin II in human plasma: technical modifications and practical experience. Clin Chim Acta 67:299-306, 1976
26. Deinum J, Derkx FHM, Schalekamp MA: Improved immunoradiometric assay for plasma renin. Clin Chem 45:847-854, 1999
27. Lachurie M-L, Azizi M, Guyenne T-T, Alhenc-Gelas F, Menard J: Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 91:2933-2942, 1995
28. Wolf G, Ziyadeh FN: The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 29:153-163, 1997
29. Chang P, Kroon I, van Dijk M, Danser A: The role of genetic heterogeneity in angiotensin-converting enzyme in physiological responses to angiotensins and bradykinin in human forearm vascular bed. J Am Soc Nephrol 9:1705A, 1998
30. Levey AS, Gassman J, Hall PM, Walker WG: Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. J Am Soc Nephrol 1:1087-1094, 1991
31. Mogensen CE: Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand J Clin Lab Invest 36:383-388, 1976
32. Parving H-H, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR: A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia 20:457-461, 1981
33. Viberti GC, Bilous RW, Mackintosh D, Keen H: Monitoring glomerular function in diabetic nephropathy. Am J Med 74:256-264, 1983
34. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH: Progression of diabetic nephropathy. Kidney Int 59:702-709, 2001
35. Lewis E, Hunsicker L, Bain R, Rhode R: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
36. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
37. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
38. Rossing P, Hommel E, Smidt UM, Parving H-H: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 45 (Suppl. 45): S145-S149, 1994
39. Rudberg S, Rasmussen LM, Bangstad H-J, Österby R: Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. Diabetes Care 23:544-548, 2000
40. Solini A, Vestra MD, Saller A, Nosadini R, Crepaldi G, Fioretto P: The angiotensin-converting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes. Diabetes 51:251-255, 2002